Skip to Main Content

Paper Details

Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance.
Clin Cancer Res
14
2021
AR, AR splice variants, AR-regulated genes, BRCA2, CRPC, CTC, CTC samples, Enzalutamide, Metastatic Castration-Resistant Prostate Cancer, PATIENTS, PTEN, RB1, RNA, TP53, androgen, androgen receptor, circulating tumor cell, enzalutamide, metastatic castration-resistant prostate cancer, patients, tumor, tumor suppression genes, tumor suppressor genes
Author NameAffiliation
Rosina T LisDana-Farber Cancer Institute
Joshua M LangCarbone Cancer Center, University of Wisconsin-Madison
Eliezer M Van AllenDana-Farber Cancer Institute
Eliezer M Van AllenDana-Farber Cancer Institute
Evan Y YuUniversity of Washington
Evan Y YuFred Hutchinson Cancer Research Center
Peter S NelsonUniversity of Washington
Peter S NelsonFred Hutchinson Cancer Research Center
Peter S NelsonUniversity of Washington
Peter S NelsonFred Hutchinson Cancer Research Center
Bruce MontgomeryUniversity of Washington
Bruce MontgomeryFred Hutchinson Cancer Research Center
Mary-Ellen TaplinDana-Farber Cancer Institute
  • 1 - 13

Datasets

Release 1.2